

# Trisomy for Synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes

Jack-Christophe Cossec<sup>1,†</sup>, Jérémie Lavour<sup>1,†</sup>, Diego E. Berman<sup>2</sup>, Isabelle Rivals<sup>3</sup>, Alexander Hoischen<sup>4</sup>, Samantha Stora<sup>5</sup>, Clémentine Ripoll<sup>6</sup>, Clotilde Mircher<sup>5</sup>, Yann Grattau<sup>5</sup>, Jean-Christophe OlivoMarin<sup>7</sup>, Fabrice de Chaumont<sup>7</sup>, Magalie Lecourtois<sup>8</sup>, Stylianos E. Antonarakis<sup>9</sup>, Joris A. Veltman<sup>4</sup>, Jean M. Delabar<sup>6</sup>, Charles Duyckaerts<sup>1</sup>, Gilbert Di Paolo<sup>2</sup>, and Marie-Claude Potier<sup>1,\*</sup>

<sup>1</sup>Centre de Recherche de l'Institut du Cerveau et de la Moelle, CNRS UMR7225, UPMC, INSERM UMRS975, Hôpital Pitié-Salpêtrière, Paris, France, <sup>2</sup>Taub Institute for Research on Alzheimer's Disease and The Aging Brain and Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA, <sup>3</sup>Equipe de Statistique Appliquée, ESPCI ParisTech, Paris, France, <sup>4</sup>Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, <sup>5</sup>Institut Jérôme Lejeune, Paris, France, <sup>6</sup>Univ Paris Diderot, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative (BFA) EAC4413 CNRS, Paris, France, <sup>7</sup>Institut Pasteur, Quantitative Image Analysis Unit, CNRS URA2582, Paris, France, <sup>8</sup>INSERM U 614, Rouen, France, <sup>9</sup>University of Geneva, Geneva, Switzerland

Received February 24, 2012; Revised and Accepted April 4, 2012

**Enlarged early endosomes have been observed in neurons and fibroblasts in Down syndrome (DS). These endosome abnormalities have been implicated in the early development of Alzheimer's disease (AD) pathology in these subjects. Here, we show the presence of enlarged endosomes in blood mononuclear cells and lymphoblastoid cell lines (LCLs) from individuals with DS using immunofluorescence and confocal microscopy. Genotype–phenotype correlations in LCLs carrying partial trisomies 21 revealed that triplication of a 2.56 Mb locus in 21q22.11 is associated with the endosomal abnormalities. This locus contains the gene encoding the phosphoinositide phosphatase synaptojanin 1 (SYNJ1), a key regulator of the signalling phospholipid phosphatidylinositol-4,5-bisphosphate that has been shown to regulate clathrin-mediated endocytosis. We found that SYNJ1 transcripts are increased in LCLs from individuals with DS and that overexpression of SYNJ1 in a neuroblastoma cell line as well as in transgenic mice leads to enlarged endosomes. Moreover, the proportion of enlarged endosomes in fibroblasts from an individual with DS was reduced after silencing SYNJ1 expression with RNA interference. In LCLs carrying amyloid precursor protein (APP) microduplications causing autosomal dominant early-onset AD, enlarged endosomes were absent, suggesting that APP overexpression alone is not involved in the modification of early endosomes in this cell type. These findings provide new insights into the contribution of SYNJ1 overexpression to the endosomal changes observed in DS and suggest an attractive new target for rescuing endocytic dysfunction and lipid metabolism in DS and in AD.**

\*To whom correspondence should be addressed at: Centre de Recherche de l'Institut du Cerveau et de la Moelle, CNRS UMR7225, UPMC, INSERM UMRS975, Hôpital Pitié-Salpêtrière, 47, Bd de l'Hôpital 75013 Paris, France. Tel: +33 157274519; Email: [marie-claude.potier@upmc.fr](mailto:marie-claude.potier@upmc.fr)

<sup>†</sup>These authors contributed equally to the work.

## INTRODUCTION

Enlarged endosomes are believed to be the first morphological change observed in Alzheimer's disease (AD) brains, preceding the deposition of amyloid- $\beta$  peptide (A $\beta$ ) (1). They are primarily found in sporadic cases with no pathological evidence of AD yet and in all individuals with Down syndrome (DS) as early as after 28 weeks of gestation, preceding AD neuropathology by decades (2). Early endosomes are a major sorting compartment of the endocytic pathway in which the amyloid precursor protein (APP) is internalized and processed, producing amyloid- $\beta$  peptides (A $\beta$ ) (3). The *APP* gene maps to 21q21, suggesting that the *APP* locus could be the major genetic determinant of AD neuropathology in DS (4–7). Following this hypothesis, it was shown that overexpression of APP is necessary, although not sufficient, for inducing endosomal anomalies in neurons from transgenic mouse models of DS (8). Additionally, over-expression of the C-terminal fragment of APP in human fibroblasts induced the AD-like endosomal phenotype (9). Rab4, Rab5 and Rab7 GTPases and early endosomal antigen 1 (EEA1) have also been shown to be overexpressed in AD and DS (2,10–12). Since overexpression of Rab5 or Rab5 mutants blocking guanosine triphosphate (GTP) hydrolysis increases the fusion of endocytic vesicles, inducing the formation of giant early endosomes, increase in Rab5 in AD and DS could also be responsible for the increase in size of early endosomes (13,14).

However, several lines of evidence suggest that human chromosome 21 (Hsa21) genes other than *APP* could contribute to the endosomal dysfunction. In familial AD, where A $\beta$  overproduction is associated with mutations in the APP or in the presenilin genes, the endosomal compartment appears to be unchanged (15). In addition, App transgenic mice carrying the Swedish mutations do not show any endosomal dysfunction (8). Finally, enlarged endosomes have been found in the brain of Ts65Dn mice, a DS mouse model that has three genomic copies of about half of the genes orthologous to human chromosome 21, including *APP*. When the number of copies of App was reduced to normal condition by crossing Ts65Dn mice with App knock-out mice, endosomal dysfunction was suppressed, suggesting that APP overexpression was necessary but not sufficient to produce enlarged endosomes (8).

We thus searched, for other genes from Hsa21 that may contribute to the observed endosomal dysfunctions in DS, using genotype–phenotype correlations. This approach had been extensively applied to identify the Down Syndrome Critical Region (DSCR) responsible for most of the clinical features of DS using cells generated from partial trisomy 21 (partial T21) cases, but had not been applied yet to a cellular phenotype (16,17). We found that blood mononuclear cells as well as lymphoblastoid cell lines (LCLs) derived from blood samples of individuals with DS carried endosomal abnormalities. We then used a collection of LCLs originating from partial T21 cases and showed that triplication of a 2.56 Mb locus from Hsa21 containing the synaptojanin1 (*SYNJ1*) gene is associated with the presence of endosomal abnormalities. *SYNJ1* is a phosphatase that catalyses the dephosphorylation of the signalling phospholipid phosphatidylinositol-4,5-bisphosphate PI(4,5)P<sub>2</sub> that has been shown to control clathrin-mediated endocytosis (18,19). *SYNJ1* levels are increased in DS brain (20) and its


overexpression in DS mouse models has been found to perturb PI(4,5)P<sub>2</sub> metabolism and contribute to cognitive deficits (21). In this study, we further show that *SYNJ1* overexpression alone is functionally linked to the enlargement of early endosomes using three different models: overexpression of *SYNJ1* in neuroblastoma cells and in neurons from transgenic mice, and *SYNJ1* inhibition in fibroblasts from an individual with DS.

## RESULTS

### Endosomal abnormalities are present in blood mononuclear cells and LCLs from individuals with DS

To compare the number and the size of endosomes of blood mononuclear cells from individuals with DS ( $n = 8$ ) and age-matched controls (euploid individuals) ( $n = 8$ ), early endosomes were labelled by immunofluorescence with an antibody against the early endosome antigen protein EEA1 (Fig. 1A). Using confocal microscopy and image analysis, we showed that the mean number of endosomes per cell in individuals with DS was not significantly different from that of euploids (Fig. 1B and Table 1; euploids 5.6, DS 4.4,  $P = 0.33$ ). Interestingly, the mean size of endosomes was significantly increased in cells from individuals with DS when compared with age-matched euploids (Fig. 1C and Table 1; euploids 119.8, DS 157.43,  $P = 1.4 \times 10^{-10}$ ). We then categorized the endosomes from DS and euploid individuals in three classes according to their size (small, medium and large), based on K-means clustering. Figure 1D shows that the percentage of large endosomes was higher (27.8%) in mononuclear blood cells from individuals with DS when compared with euploids (8.7%). Conversely, the percentage of small endosomes was lower in DS mononuclear blood cells (26.2%) when compared with euploids (44.3%) (Fig. 1D and Table 1;  $\chi^2$ -test of homogeneity  $P = 0$ ). Figure 1E shows that cells from euploids and individuals with DS could be clearly distinguished based on their content in large and small endosomes.

We then performed similar morphometric analyses of early endosomes from LCLs generated by transformation of lymphocytes from individuals with DS ( $n = 12$ ) and euploids ( $n = 9$ ) with the Epstein–Bar virus (Fig. 2A). As in mononuclear blood cells, the mean number of endosomes per cell in LCLs from DS and euploids was not statistically different (Fig. 2B and Table 1; euploids 13.0, DS 12.9,  $P = 0.84$ ). Interestingly, the mean endosome size was significantly increased in LCLs from individuals with DS when compared with euploids (Fig. 2C and Table 1; euploids 231.6, DS 250.4,  $P = 3.9 \times 10^{-4}$ ). The analysis of the size distribution of endosomes from individuals with DS and euploids using  $\chi^2$  homogeneity tests revealed that the percentage of larger endosomes was higher in DS LCLs (16.7%) when compared with euploids (11.3%) (Fig. 2D and Table 1;  $P = 7.7 \times 10^{-8}$ ). In addition, LCLs from euploids and individuals with DS could be differentiated according to the percentage of large and small endosomes (Fig. 2E). We also found a significant increase in the mean size of endosomes of DS LCLs ( $n = 3$ ) when compared with euploids ( $n = 3$ ) using immunolabelling with an anti-Rab5 antibody (data not shown).



**Figure 1.** Endosomal abnormalities are present in mononuclear blood cells from individuals with DS. (A) Immunofluorescence confocal images showing EEA1-labelled early endosomes in representative mononuclear blood cells from euploid (left) and individuals with DS (right). (B) Mean number of EEA1-positive early endosomes in DS ( $n = 8$ ) mononuclear blood cells when compared with euploids ( $n = 8$ ). (C) Mean endosome size in DS mononuclear blood cells when compared with euploids. (D) Endosome size distribution of small-, medium- and large-sized endosomes, based on K-means clustering. (E) Representation of mononuclear blood cells from euploid (green circles) and individuals with DS (red circles) in the plane defined by the percentage of their large and small endosomes. \*\*\* $P < 0.001$ .

The amounts of Rab5 and EEA1 proteins in LCLs from DS ( $n = 10$ ) and euploid ( $n = 10$ ) individuals were quantified by western blot and no significant difference was found between DS and control cells, although there was a trend for an increase in DS samples (Supplementary Material, Fig. S1;  $P = 0.1$  and  $P = 0.43$  for Rab5 and EEA1, respectively;  $t$ -test).

In conclusion, we have described a new cellular phenotype based on the morphology of early endosomes in mononuclear blood cells as well as in LCLs from individuals with DS. The presence of this phenotype in LCLs allowed us to characterize partial trisomies 21 for identifying region(s) from Hsa21 involved in the cellular phenotype.

### Endosomal abnormalities in LCLs from individuals carrying partial trisomies 21


We analysed the endosomes of LCLs from eight patients carrying partial trisomies 21 (partial T21). The extent of the partial trisomies was characterized in detail by high-resolution comparative genomic hybridization (CGH) using Hsa21-specific NimbleGen microarrays (Table 2).

We compared the endosome size distribution from each partial T21, to the distributions obtained with DS and control LCLs using  $\chi^2$ -tests (Fig. 3A and B, Table 3). This analysis revealed that three out of eight partial T21 showed

**Table 1.** Statistical analysis of the endosome characteristics

Cell type	Conditions	Mean number of endosomes/cell	Statistical tests used for mean number	<i>P</i> -values of the test of comparison of the mean numbers of endosomes/cell	Mean size of endosomes pixels <sup>2</sup>	Statistical tests used for mean size	<i>P</i> -values of the test of comparison of the mean endosome sizes	Endosome size distribution in % (small/medium/large) using K-means clustering	<i>P</i> -value of the $\chi^2$ test of comparison of the endosome size distributions																																																																																										
Mononuclear blood cells (Fig. 1)	Euploid ( <i>n</i> = 8)	5.6	Mean equality test	0.33 (NS)	119.8	Mean equality test with individual effect	$P_g = 1.4 \cdot 10^{-10}$ ; $P_1 = 2.6 \cdot 10^{-3}$	44.3/47.0/8.7	0																																																																																										
	DS ( <i>n</i> = 8)	4.4			157.4			26.2/46.0/27.8		LCLs (Fig. 2)	Euploid ( <i>n</i> = 9)	13.0	Mean equality test	0.84 (NS)	231.6	Mean equality test with individual effect	$P_g = 3.9 \cdot 10^{-4}$ ; $P_1 = 3.2 \cdot 10^{-3}$	46.3/42.4/11.3	$7.7 \cdot 10^{-8}$	DS ( <i>n</i> = 12)	12.9	250.4	45.6/37.7/16.7	Neurons from Tg(SYNJ1) mice perfused (Fig. 4)	WT ( <i>n</i> = 3)	52.0	Mean equality test	0.27 (NS)	69.2	Mean equality test with individual effect	$P_g = 2.5 \cdot 10^{-12}$ ; $P_1 = 2.1 \cdot 10^{-5}$	68.0/28.2/3.8	0	Tg(SYNJ1) ( <i>n</i> = 4)	45.5	100.6	57.1/27.8/15.1	Neurons from Tg(SYNJ1) mice non-perfused (Supplementary Material, Fig. S2)	WT ( <i>n</i> = 4)	24.7	Mean equality test	0.14 (NS)	59.2	Mean equality test with individual effect	$P_g = 1.9 \cdot 10^{-4}$ ; $P_1 = 0.12$ (NS)	62.4/32.3/5.3	$6.0 \cdot 10^{-9}$	Tg(SYNJ1) ( <i>n</i> = 4)	32.1	69.6	56.0/31.0/13.0	SH SY5Y neuroblastoma cells (Fig. 5)	NT (non-transfected) ( <i>n</i> = 31)	24.6	One-way ANOVA	$1.0 \cdot 10^{-3}$ ; $P_{NT}/P_{GFP}$ : 0.68 (NS); $P_{NT}/P_{SYNJ1}$ : $7.1 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1}$ : $2.4 \cdot 10^{-3}$	150.3	One-way ANOVA	$3.4 \cdot 10^{-2}$ ; $P_{NT}/P_{GFP}$ : 0.65 (NS); $P_{NT}/P_{SYNJ1}$ : $6.0 \cdot 10^{-2}$ ; $P_{GFP}/P_{SYNJ1}$ : $1.6 \cdot 10^{-2}$	55.4/38.2/6.4	$1.8 \cdot 10^{-5}$ ; $P_{NT}/P_{GFP} = 0.37$ (NS); $P_{NT}/P_{SYNJ1} = 6.3 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1} = 6.9 \cdot 10^{-5}$	GFP transfected ( <i>n</i> = 32)	25.8	145.2	58.7/34.8/6.5	SYNJ1 transfected ( <i>n</i> = 34)	35.2	170.3	51.1/37.3/11.6	Fibroblasts (non-transfected) (Supplementary Material, Fig. S3)	Euploid ( <i>n</i> = 20)	127.9	Mean equality test	0.70 (NS)	102.2	Mean equality test with individual effect	$2.1 \cdot 10^{-10}$	70.8/27.8/1.4	0	DS ( <i>n</i> = 20)	130.1	136.7	57.4/34.6/8.0	Fibroblasts (transfected) (Fig. 6)	Euploid random shRNA ( <i>n</i> = 45)	148.6	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 0.75$ (NS); $P_{\text{shRNA}} = 0.61$ (NS); $P_{\text{interaction}} = 0.57$ (NS)	96.2	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 3.2 \cdot 10^{-6}$ ; $P_{\text{shRNA}} = 0.15$ (NS); $P_{\text{interaction}} = 0.46$ (NS)	61.3/35.2/3.5	0; $P_{\text{euploid (random-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (SYNJ1-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (random-sh)}/\text{euploid (SYNJ1-sh)}} = 0.12$ (NS); $P_{\text{(random-sh)}/\text{DS (SYNJ1-sh)}} = 7.4 \cdot 10^{-4}$	DS random shRNA ( <i>n</i> = 45)	150.5	108.3	54.3/38.5/7.2	Euploid SYNJ1-shRNA ( <i>n</i> = 45)	149.0
LCLs (Fig. 2)	Euploid ( <i>n</i> = 9)	13.0	Mean equality test	0.84 (NS)	231.6	Mean equality test with individual effect	$P_g = 3.9 \cdot 10^{-4}$ ; $P_1 = 3.2 \cdot 10^{-3}$	46.3/42.4/11.3	$7.7 \cdot 10^{-8}$																																																																																										
	DS ( <i>n</i> = 12)	12.9			250.4			45.6/37.7/16.7		Neurons from Tg(SYNJ1) mice perfused (Fig. 4)	WT ( <i>n</i> = 3)	52.0	Mean equality test	0.27 (NS)	69.2	Mean equality test with individual effect	$P_g = 2.5 \cdot 10^{-12}$ ; $P_1 = 2.1 \cdot 10^{-5}$	68.0/28.2/3.8	0	Tg(SYNJ1) ( <i>n</i> = 4)	45.5	100.6	57.1/27.8/15.1	Neurons from Tg(SYNJ1) mice non-perfused (Supplementary Material, Fig. S2)	WT ( <i>n</i> = 4)	24.7	Mean equality test	0.14 (NS)	59.2	Mean equality test with individual effect	$P_g = 1.9 \cdot 10^{-4}$ ; $P_1 = 0.12$ (NS)	62.4/32.3/5.3	$6.0 \cdot 10^{-9}$	Tg(SYNJ1) ( <i>n</i> = 4)	32.1	69.6	56.0/31.0/13.0	SH SY5Y neuroblastoma cells (Fig. 5)	NT (non-transfected) ( <i>n</i> = 31)	24.6	One-way ANOVA	$1.0 \cdot 10^{-3}$ ; $P_{NT}/P_{GFP}$ : 0.68 (NS); $P_{NT}/P_{SYNJ1}$ : $7.1 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1}$ : $2.4 \cdot 10^{-3}$	150.3	One-way ANOVA	$3.4 \cdot 10^{-2}$ ; $P_{NT}/P_{GFP}$ : 0.65 (NS); $P_{NT}/P_{SYNJ1}$ : $6.0 \cdot 10^{-2}$ ; $P_{GFP}/P_{SYNJ1}$ : $1.6 \cdot 10^{-2}$	55.4/38.2/6.4	$1.8 \cdot 10^{-5}$ ; $P_{NT}/P_{GFP} = 0.37$ (NS); $P_{NT}/P_{SYNJ1} = 6.3 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1} = 6.9 \cdot 10^{-5}$	GFP transfected ( <i>n</i> = 32)	25.8	145.2	58.7/34.8/6.5		SYNJ1 transfected ( <i>n</i> = 34)	35.2			170.3			51.1/37.3/11.6		Fibroblasts (non-transfected) (Supplementary Material, Fig. S3)	Euploid ( <i>n</i> = 20)	127.9	Mean equality test	0.70 (NS)	102.2	Mean equality test with individual effect	$2.1 \cdot 10^{-10}$	70.8/27.8/1.4	0	DS ( <i>n</i> = 20)	130.1	136.7	57.4/34.6/8.0	Fibroblasts (transfected) (Fig. 6)	Euploid random shRNA ( <i>n</i> = 45)	148.6	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 0.75$ (NS); $P_{\text{shRNA}} = 0.61$ (NS); $P_{\text{interaction}} = 0.57$ (NS)	96.2	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 3.2 \cdot 10^{-6}$ ; $P_{\text{shRNA}} = 0.15$ (NS); $P_{\text{interaction}} = 0.46$ (NS)		61.3/35.2/3.5	0; $P_{\text{euploid (random-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (SYNJ1-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (random-sh)}/\text{euploid (SYNJ1-sh)}} = 0.12$ (NS); $P_{\text{(random-sh)}/\text{DS (SYNJ1-sh)}} = 7.4 \cdot 10^{-4}$			DS random shRNA ( <i>n</i> = 45)			150.5		108.3	54.3/38.5/7.2	Euploid SYNJ1-shRNA ( <i>n</i> = 45)	149.0	89.5	67.1/35.4/2.9
Neurons from Tg(SYNJ1) mice perfused (Fig. 4)	WT ( <i>n</i> = 3)	52.0	Mean equality test	0.27 (NS)	69.2	Mean equality test with individual effect	$P_g = 2.5 \cdot 10^{-12}$ ; $P_1 = 2.1 \cdot 10^{-5}$	68.0/28.2/3.8	0																																																																																										
	Tg(SYNJ1) ( <i>n</i> = 4)	45.5			100.6			57.1/27.8/15.1		Neurons from Tg(SYNJ1) mice non-perfused (Supplementary Material, Fig. S2)	WT ( <i>n</i> = 4)	24.7	Mean equality test	0.14 (NS)	59.2	Mean equality test with individual effect	$P_g = 1.9 \cdot 10^{-4}$ ; $P_1 = 0.12$ (NS)	62.4/32.3/5.3	$6.0 \cdot 10^{-9}$	Tg(SYNJ1) ( <i>n</i> = 4)	32.1	69.6	56.0/31.0/13.0	SH SY5Y neuroblastoma cells (Fig. 5)	NT (non-transfected) ( <i>n</i> = 31)	24.6	One-way ANOVA	$1.0 \cdot 10^{-3}$ ; $P_{NT}/P_{GFP}$ : 0.68 (NS); $P_{NT}/P_{SYNJ1}$ : $7.1 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1}$ : $2.4 \cdot 10^{-3}$	150.3	One-way ANOVA	$3.4 \cdot 10^{-2}$ ; $P_{NT}/P_{GFP}$ : 0.65 (NS); $P_{NT}/P_{SYNJ1}$ : $6.0 \cdot 10^{-2}$ ; $P_{GFP}/P_{SYNJ1}$ : $1.6 \cdot 10^{-2}$	55.4/38.2/6.4	$1.8 \cdot 10^{-5}$ ; $P_{NT}/P_{GFP} = 0.37$ (NS); $P_{NT}/P_{SYNJ1} = 6.3 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1} = 6.9 \cdot 10^{-5}$	GFP transfected ( <i>n</i> = 32)	25.8	145.2	58.7/34.8/6.5		SYNJ1 transfected ( <i>n</i> = 34)	35.2			170.3			51.1/37.3/11.6		Fibroblasts (non-transfected) (Supplementary Material, Fig. S3)	Euploid ( <i>n</i> = 20)	127.9	Mean equality test	0.70 (NS)	102.2	Mean equality test with individual effect	$2.1 \cdot 10^{-10}$	70.8/27.8/1.4	0	DS ( <i>n</i> = 20)	130.1	136.7	57.4/34.6/8.0	Fibroblasts (transfected) (Fig. 6)	Euploid random shRNA ( <i>n</i> = 45)	148.6	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 0.75$ (NS); $P_{\text{shRNA}} = 0.61$ (NS); $P_{\text{interaction}} = 0.57$ (NS)	96.2	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 3.2 \cdot 10^{-6}$ ; $P_{\text{shRNA}} = 0.15$ (NS); $P_{\text{interaction}} = 0.46$ (NS)	61.3/35.2/3.5	0; $P_{\text{euploid (random-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (SYNJ1-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (random-sh)}/\text{euploid (SYNJ1-sh)}} = 0.12$ (NS); $P_{\text{(random-sh)}/\text{DS (SYNJ1-sh)}} = 7.4 \cdot 10^{-4}$	DS random shRNA ( <i>n</i> = 45)	150.5	108.3	54.3/38.5/7.2		Euploid SYNJ1-shRNA ( <i>n</i> = 45)	149.0			89.5			67.1/35.4/2.9	DS SYNJ1-shRNA ( <i>n</i> = 45)		142.1	106.2	54.8/39.6/5.6										
Neurons from Tg(SYNJ1) mice non-perfused (Supplementary Material, Fig. S2)	WT ( <i>n</i> = 4)	24.7	Mean equality test	0.14 (NS)	59.2	Mean equality test with individual effect	$P_g = 1.9 \cdot 10^{-4}$ ; $P_1 = 0.12$ (NS)	62.4/32.3/5.3	$6.0 \cdot 10^{-9}$																																																																																										
	Tg(SYNJ1) ( <i>n</i> = 4)	32.1			69.6			56.0/31.0/13.0		SH SY5Y neuroblastoma cells (Fig. 5)	NT (non-transfected) ( <i>n</i> = 31)	24.6	One-way ANOVA	$1.0 \cdot 10^{-3}$ ; $P_{NT}/P_{GFP}$ : 0.68 (NS); $P_{NT}/P_{SYNJ1}$ : $7.1 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1}$ : $2.4 \cdot 10^{-3}$	150.3	One-way ANOVA	$3.4 \cdot 10^{-2}$ ; $P_{NT}/P_{GFP}$ : 0.65 (NS); $P_{NT}/P_{SYNJ1}$ : $6.0 \cdot 10^{-2}$ ; $P_{GFP}/P_{SYNJ1}$ : $1.6 \cdot 10^{-2}$	55.4/38.2/6.4	$1.8 \cdot 10^{-5}$ ; $P_{NT}/P_{GFP} = 0.37$ (NS); $P_{NT}/P_{SYNJ1} = 6.3 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1} = 6.9 \cdot 10^{-5}$	GFP transfected ( <i>n</i> = 32)	25.8	145.2	58.7/34.8/6.5		SYNJ1 transfected ( <i>n</i> = 34)	35.2			170.3			51.1/37.3/11.6		Fibroblasts (non-transfected) (Supplementary Material, Fig. S3)	Euploid ( <i>n</i> = 20)	127.9	Mean equality test	0.70 (NS)	102.2	Mean equality test with individual effect	$2.1 \cdot 10^{-10}$	70.8/27.8/1.4	0	DS ( <i>n</i> = 20)	130.1	136.7	57.4/34.6/8.0	Fibroblasts (transfected) (Fig. 6)	Euploid random shRNA ( <i>n</i> = 45)	148.6	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 0.75$ (NS); $P_{\text{shRNA}} = 0.61$ (NS); $P_{\text{interaction}} = 0.57$ (NS)	96.2	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 3.2 \cdot 10^{-6}$ ; $P_{\text{shRNA}} = 0.15$ (NS); $P_{\text{interaction}} = 0.46$ (NS)	61.3/35.2/3.5	0; $P_{\text{euploid (random-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (SYNJ1-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (random-sh)}/\text{euploid (SYNJ1-sh)}} = 0.12$ (NS); $P_{\text{(random-sh)}/\text{DS (SYNJ1-sh)}} = 7.4 \cdot 10^{-4}$	DS random shRNA ( <i>n</i> = 45)	150.5	108.3	54.3/38.5/7.2		Euploid SYNJ1-shRNA ( <i>n</i> = 45)	149.0			89.5			67.1/35.4/2.9		DS SYNJ1-shRNA ( <i>n</i> = 45)	142.1	106.2	54.8/39.6/5.6																								
SH SY5Y neuroblastoma cells (Fig. 5)	NT (non-transfected) ( <i>n</i> = 31)	24.6	One-way ANOVA	$1.0 \cdot 10^{-3}$ ; $P_{NT}/P_{GFP}$ : 0.68 (NS); $P_{NT}/P_{SYNJ1}$ : $7.1 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1}$ : $2.4 \cdot 10^{-3}$	150.3	One-way ANOVA	$3.4 \cdot 10^{-2}$ ; $P_{NT}/P_{GFP}$ : 0.65 (NS); $P_{NT}/P_{SYNJ1}$ : $6.0 \cdot 10^{-2}$ ; $P_{GFP}/P_{SYNJ1}$ : $1.6 \cdot 10^{-2}$	55.4/38.2/6.4	$1.8 \cdot 10^{-5}$ ; $P_{NT}/P_{GFP} = 0.37$ (NS); $P_{NT}/P_{SYNJ1} = 6.3 \cdot 10^{-4}$ ; $P_{GFP}/P_{SYNJ1} = 6.9 \cdot 10^{-5}$																																																																																										
	GFP transfected ( <i>n</i> = 32)	25.8			145.2			58.7/34.8/6.5																																																																																											
	SYNJ1 transfected ( <i>n</i> = 34)	35.2			170.3			51.1/37.3/11.6																																																																																											
Fibroblasts (non-transfected) (Supplementary Material, Fig. S3)	Euploid ( <i>n</i> = 20)	127.9	Mean equality test	0.70 (NS)	102.2	Mean equality test with individual effect	$2.1 \cdot 10^{-10}$	70.8/27.8/1.4	0																																																																																										
	DS ( <i>n</i> = 20)	130.1			136.7			57.4/34.6/8.0																																																																																											
Fibroblasts (transfected) (Fig. 6)	Euploid random shRNA ( <i>n</i> = 45)	148.6	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 0.75$ (NS); $P_{\text{shRNA}} = 0.61$ (NS); $P_{\text{interaction}} = 0.57$ (NS)	96.2	Two-way ANOVA	$P_{\text{euploid}/\text{DS}} = 3.2 \cdot 10^{-6}$ ; $P_{\text{shRNA}} = 0.15$ (NS); $P_{\text{interaction}} = 0.46$ (NS)	61.3/35.2/3.5	0; $P_{\text{euploid (random-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (SYNJ1-sh)}} = 0$ ; $P_{\text{euploid (SYNJ1-sh)}/\text{DS (random-sh)}} = 0$ ; $P_{\text{euploid (random-sh)}/\text{euploid (SYNJ1-sh)}} = 0.12$ (NS); $P_{\text{(random-sh)}/\text{DS (SYNJ1-sh)}} = 7.4 \cdot 10^{-4}$																																																																																										
	DS random shRNA ( <i>n</i> = 45)	150.5			108.3			54.3/38.5/7.2																																																																																											
	Euploid SYNJ1-shRNA ( <i>n</i> = 45)	149.0			89.5			67.1/35.4/2.9																																																																																											
	DS SYNJ1-shRNA ( <i>n</i> = 45)	142.1			106.2			54.8/39.6/5.6																																																																																											

In the 'Conditions' column, the numbers in parentheses are the numbers of individuals. For the tests of comparison of the mean endosome sizes, the *P*-values  $P_g$  and  $P_1$  refer to the significance of the genotype and individual effects, respectively. For the SH SY5Y neuroblastoma experiment, we indicate four *P*-values: the ones at the top correspond to the comparison of the three conditions [not transfected (NT), GFP or SYNJ1 transfected], and the *P*-values below correspond to two-by-two comparisons. For comparing the mean endosome number and size of transfected fibroblasts, we applied a two-way ANOVA:  $P_{\text{euploid}/\text{DS}}$  corresponds to the test of the effect of genotype,  $P_{\text{shRNA}}$  to that of treatment, and  $P_{\text{interaction}}$  to that of their interaction. The first *P*-value given for the  $\chi^2$  tests corresponds to the test of homogeneity of all four conditions, the *P*-values below are those of the two-by-two comparisons. ANOVA, analysis of variance.



**Figure 2.** Enlarged endosomes are present in LCLs from individuals with DS. (A) Representative confocal images of EEA1-positive early endosomes of LCLs from euploids and individuals with DS. (B) Mean number of EEA1-positive early endosomes in DS ( $n = 12$ ) when compared with euploids ( $n = 9$ ) LCLs. (C) Mean endosome size in LCLs from DS when compared with euploids. (D) Endosome size distribution of small-, medium- and large-sized endosomes, based on K-means clustering. (E) Representation of LCLs from euploid (green circles) and individuals with DS (red circles) in the plane defined by the percentage of their large and small endosomes.  $***P < 0.001$ .

endosome size distributions similar to individuals with DS, indicating that LCLs from these partial T21 (numbers 3, 4 and 5) contained endosomal abnormalities (Fig. 3B and C and Table 3). Interestingly, endosomal dysmorphologies were absent in LCLs 7 and 8 carrying APP microduplications causing autosomal dominant early-onset AD (22) (Fig. 3A showing partial T21 number 8). We concluded that APP gene dosage imbalance was not involved in the phenotype in this cell type where APP was barely detectable in the control situation (23,24).

By correlating the presence of enlarged endosomes detected by immunofluorescence to the chromosomal segment triplicated, we isolated a 2.56 Mb region from Hsa21 located in 21q22.1 from position 31,778,250 to position 34,343,750 (Fig. 3B, Table 2). This segment contains 33 genes or predictions among which 14 are expressed in LCLs according to expression microarray data or quantitative polymerase chain reaction (PCR): *SOD1*, *SFRS15*, *SYNJ1*, *C21ORF66*, *IFAR2*, *IL10RB*, *IFNAR1*, *IFNGR2*, *TMEM50B*, *GART*, *SON*, *CRYZL1*, *DONSON* and *ATP50* (Table 4) (23,24) (M.C.P. and J.M.D., unpublished data).

**Table 2.** Results of ultra-high-resolution array CGH for partial trisomies 21 and APP microduplications (7 and 8)

Present ID of LCL	Aberration 1		Aberration 2		Aberration size (Mb)
	Start (bp)	End (bp)	Start (bp)	End (bp)	
7, F037 <sup>a</sup>	25,614,750	26,605,250	–	–	0.991
8, F028 <sup>a</sup>	25,922,750	26,489,750	–	–	0.567
1	14,400,000	29,128,750	37,843,750	qter	23.829
2	18,982,250	18,999,750	36,426,250	42,589,750	6.181
3	21,047,250	qter	–	–	25.897
4	28,390,250	qter	–	–	18.554
5	31,778,250	qter	–	–	15.166
6	34,343,750	43,706,250	44,896,250	46,422,250	10.889

Positions are deduced from hg18 on UCSC browser 2006 built.

<sup>a</sup>From Reference (22).

From this list, *SYNJ1* appeared as a strong candidate for the observed phenotype. Indeed, previous studies reported that *SYNJ1* is involved in vesicle recycling and clathrin-mediated endocytosis (25,26). In addition, *SYNJ1* protein levels are increased in post-mortem DS brains (20,27). Interestingly, using real-time quantitative PCR, we found that *SYNJ1* transcripts show a 2.24-fold significant increase in LCLs from individuals with DS when compared with euploids ( $n = 3$ ,  $P = 0.032$ ,  $t$ -test). In addition, correlation between the presence of endosomal dysmorphologies in individuals with partial T21 and *SYNJ1* expression levels was non-significant ( $r = 0.46$ ), because of lack of partial T21 LCLs available (Table 5). However, for *RAB5* and *SOD1*, these correlations were lower ( $r = 0.03$  and  $r = 0.38$  respectively, Table 5). Based on these findings, we investigated the contribution of *SYNJ1* in the observed phenotype.

#### SYNJ1 overexpression in SH-SY5Y cells induces DS-like endosome enlargement

SH-SY5Y neuroblastoma cells were transfected with the human *SYNJ1* cDNA long isoform (170Kd) flag-tagged or a GFP cDNA as a control (Fig. 4A). Endosomes were labelled as described above with an anti-EEA1 antibody. Image analysis revealed that the mean number of endosomes per cell was increased in cells overexpressing *SYNJ1* (Fig. 4B and Table 1; non-transfected 24.6, GFP 25.8, *SYNJ1* 35.2,  $P = 1.0 \times 10^{-3}$ ). Interestingly, the mean endosome size in cells overexpressing *SYNJ1* was increased by 18% when compared with controls (Fig. 4C; non-transfected 150.3, GFP 145.2, *SYNJ1* 170.3,  $P = 3.4 \times 10^{-2}$ ). Analysis of the endosome size distributions showed that the percentage of larger endosomes was significantly higher in *SYNJ1*-transfected cells (11.6%) when compared with control cells (6.5%) (Fig. 4D and E and Table 1;  $P = 1.8 \times 10^{-5}$ ). We thus concluded that *SYNJ1* overexpression induces morphological changes of the early EEA1-positive early endosomes.


#### Neurons from the prefrontal cortex of transgenic mice overexpressing SYNJ1 show endosomal abnormalities

We then analysed the morphology of EEA1-positive endosomes in the brain of transgenic mice carrying one additional copy of the mouse *Synj1* gene (21). Figure 5A shows a

significant increase in *Synj1* in the brain of Tg(*SYNJ1*) mice ( $n = 4$ ,  $P = 0.02$   $t$ -test), as described previously (21). Endosomes were analysed in the prefrontal cortex where labelling was the strongest, in neurons double-labelled with anti-MAP2 and anti-EEA1 antibodies (Fig. 5B). The mean number of endosomes per neuron in Tg(*SYNJ1*) was not found to be significantly different from that of controls, both for perfused and non-perfused brains [Fig. 5C, Supplementary Material, Fig. S2B and Table S1; perfused WT 52.0, Tg(*SYNJ1*) 45.5,  $P = 0.27$ ; non-perfused WT 24.7, Tg(*SYNJ1*) 32.01,  $P = 0.14$ ]. However, morphometric analysis revealed a significant 1.45-fold increase in the mean endosome size in transgenic mice overexpressing *Synj1* when compared with WT mice, with both fixation methods (Fig. 5D, Supplementary Material, Fig. S2C and Table S1; perfused WT 69.2, Tg(*SYNJ1*) 100.6,  $P = 2.5 \times 10^{-12}$ ; non-perfused WT 59.2, Tg(*SYNJ1*) 69.6,  $P = 1.9 \times 10^{-4}$ ). As for the other cell types analysed, the significant increase in mean endosome size was due to a higher percentage of large EEA1-positive endosomes in Tg(*SYNJ1*) mice when compared with WT (Fig. 5E and F, Supplementary Material, Fig. S2D and E and Table 1; perfused large WT 3.8% and Tg*Synj1* 15.1%,  $P = 0$ , non-perfused WT 5.3% and Tg*Synj1* 13.0%,  $P = 6.0 \times 10^{-9}$ ). In conclusion, we showed that overexpression of *SYNJ1* in transgenic mice leads to the enlargement of early endosomes of neurons.

#### Endosomal abnormalities in DS fibroblasts are partially rescued by selectively reducing SYNJ1 expression

We performed morphometric analyses of EEA1-positive endosomes in cultured fibroblasts from one euploid and one individual with DS, which had been previously shown to contain enlarged endosomes (9) (Supplementary Material, Fig. S3A). Mean number of endosomes per cell was not statistically different in DS fibroblast when compared with euploids (Supplementary Material, Fig. S3B, euploids 127.9, DS 130.1,  $P = 0.70$ ), while the mean size of endosomes was significantly increased in DS fibroblasts when compared with euploids (Supplementary Material, Fig. S3C, euploids 102.2, DS 136.7,  $P = 2.1 \times 10^{-10}$ ). The size distributions of endosomes from DS and euploid fibroblasts were significantly different, with the percentage of larger endosomes higher in DS fibroblasts (8%) when compared with euploids (1.4%) (Supplementary Material, Fig. S3D,  $P = 0$ ).



**Figure 3.** Mapping of the chromosomal region from Hsa21 responsible for the abnormal endosome phenotype in DS. (A) Representative confocal images of EEA1-positive early endosomes in LCLs from individuals with partial trisomies 21 (partial T21) with normal-sized endosomes (Nos 6 and 8) and with abnormal endosomes (No. 4). (B) LCLs from eight partial trisomies 21 (Nos 7 and 8 correspond to APP microduplications) were characterized by CGH (Table 2) and analysed for their endosome size. +/- indicate the presence/absence of enlarged endosomes according to statistical analysis of the size distribution of their endosome (Table 3). Bottom shows the 2.56 Mb candidate region associated with endosomal abnormalities. (C) Representation of the LCLs from euploid (green circle) and from individuals carrying either full trisomies 21 (red circle) or partial T21 (red open circles with numbers corresponding to B and Table 2) in the plane defined by the percentage of large and small endosomes in their LCLs. +/- indicate the presence/absence of enlarged endosomes.

We and others showed that *SYNJ1* transcripts are overexpressed in fibroblasts from individuals with DS [1.5-fold increase  $n = 3$   $P = 0.03$   $t$ -test; and (24)]. We thus tested

whether reducing *SYNJ1* expression in these cells would decrease the proportion of enlarged endosomes. *SYNJ1* expression inhibition was initially validated in HEK293 cells

**Table 3.** Classification of the partial trisomies according to the size distribution of their endosome sizes

Partial T21 number	Homogeneity tests $\chi^2$ $P$ -values, euploid/pT21	Homogeneity tests $\chi^2$ $P$ -values, DS/pT21	Endosome size classification
1	$P_{\text{euploid/no } 1} = 0.38$	$P_{\text{DS/no } 1} = 0.13$	–
2	$P_{\text{euploid/no } 2} = 0.5$	$P_{\text{DS/no } 2} = 0.34$	–
3	$P_{\text{euploid/no } 3} = 0.12$	$P_{\text{DS/no } 3} = 0.2$	+
4	$P_{\text{euploid/no } 4} = 5.2\text{e-}05$	$P_{\text{DS/no } 4} = 0.14$	++
5	$P_{\text{euploid/no } 5} = 0.00012$	$P_{\text{DS/no } 5} = 0.38$	++
6	$P_{\text{euploid/no } 6} = 0.89$	$P_{\text{DS/no } 6} = 0.022$	--
7 (APP microduplication)	$P_{\text{euploid/no } 7} = 1$	$P_{\text{DS/no } 7} = 0.074$	–
8 (APP microduplication)	$P_{\text{euploid/no } 8} = 0.073$	$P_{\text{DS/no } 8} = 0.00018$	--

For each partial trisomy LCL, the  $P$ -values  $P_{\text{euploid}}$  and  $P_{\text{DS}}$  are those of the  $\chi^2$  tests of homogeneity of its endosome size distribution with that of the euploid and DS LCLs, respectively. When  $P_{\text{euploid}} < 5\%$  and  $P_{\text{DS}} \geq 5\%$ , the partial trisomy is classified with confidence into the enlarged endosome phenotype (++), and conversely when  $P_{\text{euploid}} \geq 5\%$  and  $P_{\text{DS}} < 5\%$  (--); otherwise, the classification is weak (+ or –).

**Table 4.** List of genes mapping to the 2.56 Mb chromosomal segment from Hsa21 functionally associated to the endosomal abnormalities in DS

Gene present on locus	Function
TIAM-1	
SOD1	Antioxydant mechanisms involved in down syndrome phenotype
SFR15	Provide a link between transcription and pre-mRNA splicing. Alternatively spliced transcript variants have been described
HUNK	
C21ORF45	
MRAP	
FALP	
URB	
SNORA80	
C21ORF63	
TCP10	
C21ORF77	
C21ORF59	
SYNJ1	Polyphosphatase involved in endocytosis
C21ORF66	Transcription encodes a protein that may bind to GC-rich DNA sequences, which suggests its involvement in the regulation of transcription
C21ORF49	
C21ORF62	
OLIG1	
OLIG2	
IFNAR2	Inflammation. The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2 inflammation
IL10RB	The protein encoded by this gene belongs to the cytokine receptor family. It is an accessory chain essential for the active interleukin 10 receptor complex. Coexpression of this and IL10RA proteins has been shown to be required for IL10-induced signal transduction
IFNAR1	The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2
IFNGR2	This gene (IFNGR2) encodes the non-ligand-binding beta chain of the gamma interferon receptor. Human interferon-gamma
TMEM50B	Encodes a predicted transmembrane protein over-expressed during cerebellar development in a Down syndrome mouse model, Tmem50b, is a developmentally regulated intracellular ER and Golgi apparatus membrane protein that may prove important for correct brain development through functions associated with precursor cells and glia
C21ORF4	
DNAJC28	
GART	The protein encoded by this gene is a trifunctional polypeptide. It has phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase activity which is required for <i>de novo</i> purine biosynthesis
SON	
DONSON	This gene lies downstream of the SON gene and spans 10 kb on chromosome 21. The function of this gene is unknown.
CRYZL1	This gene encodes a protein that has sequence similarity to zeta crystallin, also known as quinone oxidoreductase. This zeta crystallin-like protein also contains an NAD(P)H-binding site. Alternatively, spliced transcript variants have been observed but their full-length nature has not been completely determined
C21ORF60	
ITSN1	
ATP50	This ATP50 subunit is a key structural component of the stalk of the mitochondrial respiratory chain F1F0-ATP synthase and as such may contribute in a gene dosage-dependent manner to the phenotype of Down syndrome (trisomy 21)
CR626360	

Genes expressed in LCLs are highlighted in grey.



**Table 5.** Correlations of endosomal dysmorphology analysed in LCLs from individuals with partial T21 with gene expression levels evaluated using Pearson's correlation coefficient and the associated two-sided *P*-values

Gene	Correlation with the 'enlarged endosome' phenotype <i>r</i>	<i>P</i> -value
Rab5	0.03	0.92
Synj1	0.46	0.13
Sod1	0.38	0.22

expressing human cDNAs encoding Flag-tagged constructs of the long (170Kd) or short (145Kd) isoforms of *SYNJ1* together with plasmids expressing either *SYNJ1*-shRNA or random-shRNA GFP-tagged. Supplementary Material, Figure S4A and B shows that *SYNJ1*-shRNA decreased significantly the expression of the long and short isoforms of *SYNJ1* by 65 and 55%, respectively, as revealed by western blot and immunocytochemistry [ $P = 0.017$  and  $P = 0.016$  for the long and short isoforms, respectively; one-way analysis of variance (ANOVA)]. We next transfected DS and euploid fibroblasts with either *SYNJ1*-shRNA or random-shRNA. After 72 h, cells were fixed and labelled with anti-EEA1 antibody (Fig. 6A). Image analysis revealed that the mean numbers of endosomes per cell in DS and euploid fibroblasts transfected with *SYNJ1*-shRNA or random-shRNA were not statistically different (Fig. 6B, two-way ANOVA  $P = 0.75$  for genotype,  $P = 0.61$  for treatment and  $P = 0.58$  for the interaction between genotype and treatment). Importantly, the mean endosome size in fibroblasts from individuals with DS was significantly higher than the one from euploid fibroblasts after transfection with random shRNA, but the effect of *SYNJ1*-shRNA transfection on the mean endosome size was not significant (Fig. 6C, euploid 96.2, DS 108.3,  $P = 3.2 \times 10^{-6}$  for genotype,  $P = 0.15$  for treatment and  $P = 0.46$  for the interaction). However, the analysis of the size distributions of endosomes from DS fibroblasts transfected with *SYNJ1* shRNA or random shRNA using  $\chi^2$  homogeneity tests showed a significant difference, with the percentage of larger endosomes 1.3-fold lower in *SYNJ1*-shRNA-transfected DS fibroblasts (5.6%) when compared with random-shRNA-transfected DS fibroblasts (7.2%) (Fig. 6D,  $P = 7.4 \times 10^{-4}$ ). Altogether, these results strongly suggest the involvement of *SYNJ1* expression in the enlarged endosome phenotype.


## DISCUSSION

This study is the first to describe a cellular phenotype in blood cells and LCLs from individuals with DS: the presence of abnormally large endosomes using immunofluorescence labelling and confocal microscopy. Endosomal abnormalities in DS are thus not restricted to neurons and fibroblasts as demonstrated earlier (2,11). However, only peripheral cells appear to all contain enlarged endosomes, while in the brain not all neurons have enlarged endosomes and their percentage increases with age (2). In DS, endosomal abnormalities result from the direct or indirect overexpression of genes from Hsa21 that are at dosage imbalance. We searched for

these genes from Hsa21 by studying genotype–phenotype correlations in LCLs carrying partial trisomies 21. We have shown that triplication of a 2.56 Mb locus from Hsa21 is associated with the presence of endosomal abnormalities. This chromosomal segment contains 33 genes or predictions among which 14 are expressed in LCLs: *SOD1*, *SFRS15*, *SYNJ1*, *C21ORF66*, *IFAR2*, *IL10RB*, *IFNAR1*, *IFNGR2*, *TMEM50B*, *GART*, *SON*, *CRYZL1*, *DONSON* and *ATP50*. To our knowledge, only one (*SYNJ1*) is involved in endocytosis. The functions of the others can be categorized in three main groups: (i) inflammation-related genes (*IFAR2*, *IL10RB*, *IFNAR1* and *IFNGR2*), (ii) mitochondria metabolism genes (*CRYZL1* and *ATP50*) and (iii) transcription/translation genes (*SFRS15*, *C21ORF66* and *GART*) (Table 4). *TMEM50B* has been localized in the endoplasmic reticulum and in the Golgi apparatus (28), while *SON* and *DONSON* are involved in mRNA processing and gene expression (29). Although we cannot completely rule out a putative role of these genes in the formation of enlarged endosomes in DS, we focused on *SOD1* and *SYNJ1* which are particularly relevant to DS phenotypes (21,30). We knew from our previous work that *SOD1* and *SYNJ1* transcripts are increased in LCLs (23). *SOD1* was shown not to be involved in the enlarged endosome phenotype (9). Interestingly, we found that *SYNJ1* overexpression in SH-SY5Y and in Tg(*SYNJ1*) mice produced morphological changes of the early endosomes apparently similar to the one observed in blood cells or LCLs. Conversely, we showed that reducing *SYNJ1* expression in DS fibroblasts decreases the number of enlarged endosomes. Although in these conditions, the endosomal phenotype was not fully rescued, we can speculate that this may either be due to the residual expression of *SYNJ1*, resisting to the shRNA treatment, as suggested by the partial knockdown shown in Supplementary Material, Figure S4, or to the existence of other genes contributing to this phenotype.

The *SYNJ1* gene codes for the phosphoinositide phosphatase *SYNJ1*, which dephosphorylates most phosphoinositides through the combined action of its central inositol 5-phosphatase domain and NH<sub>2</sub>-terminal Sac1 domain. Among all the phosphoinositides, PI(4,5)P<sub>2</sub> appears to be a key substrate for *SYNJ1*, which dephosphorylates this lipid on the 5' position via its 5-phosphatase domain (18,21,31,32). PI(4,5)P<sub>2</sub> controls a variety of phenomena at the plasma membrane-cytosol interface, including clathrin-mediated endocytosis and the recycling of synaptic vesicles (26,31). Interestingly, *SYNJ1* overexpression in CHO cells causes a redistribution of Eps15, clathrin and  $\alpha$ -adaptin into large clusters (33). Moreover, abnormal synaptic morphology has been observed in flies overexpressing *Synj1*, and is associated with lower [PI(4,5)P<sub>2</sub>] levels (34). Finally, *SYNJ1* has been shown to be increased in post-mortem DS brains (20,27) and overexpression of this gene in DS mouse models was shown to cause a decrease in the levels of PI(4,5)P<sub>2</sub> and cognitive deficits (21).

The involvement of *SYNJ1* in endosomal abnormalities is consistent with the finding that the 145 kDa isoform interacts with endocytic SH3 domain-containing proteins, such as endophilin, amphiphysin and intersectin, while the 170 kDa isoform also interacts with clathrin, AP-2 and Eps15 (33,35–37). Both lipid phosphatase domains of *SYNJ1* are required for proper synaptic vesicle internalization, although



**Figure 4.** SYNJ1 overexpression induces DS-like endosomal dysmorphologies in SH-SY5Y neuroblastoma cells. **(A)** Representative confocal images of EEA1-positive early endosomes (in red) from SH-SY5Y neuroblastoma cells transfected or not with the Flag-SYNJ1 plasmid or the GFP plasmid; transfected cells (in green) were visualized using either an anti-Flag monoclonal antibody (SYNJ1-transfected) or by direct detection of GFP fluorescence (GFP-transfected cells). White arrows indicate endosomal abnormalities in cells overexpressing Flag-SYNJ1. **(B)** Mean number of EEA1-positive early endosomes in SH-SY5Y neuroblastoma cells transfected with SYNJ1 ( $n = 34$ ) when compared with controls ( $n = 31$  for non-transfected and  $n = 32$  for GFP-transfected). **(C)** Mean endosome size in SH-SY5Y neuroblastoma cells transfected with SYNJ1 ( $n = 34$ ) when compared with controls ( $n = 31$  for non-transfected and  $n = 32$  for GFP-transfected). **(D)** Endosome size distribution of small-, medium- and large-sized endosomes, based on K-means clustering. **(E)** Representation of the SH-SY5Y neuroblastoma cells transfected (filled circle) or not (open circle) with the Flag-SYNJ1 plasmid (red) or the GFP plasmid (green) in the plane defined by their percentage of large and small endosomes. \*\*\* $P < 0.0001$ , \*\* $P < 0.001$ , \* $P < 0.05$ .


the 5-phosphatase domain appears to play a dominant role (18), consistent with the well-established role of PI(4,5)P<sub>2</sub> in clathrin-mediated endocytosis (32). Indeed, PI(4,5)P<sub>2</sub> control the recruitment of clathrin adaptors to the cell surface as well as a number of accessory factors that are critical for clathrin-mediated endocytosis, including the fission factor dynamin. Decrease in intracellular PI(4,5)P<sub>2</sub> levels achieved by either overexpression of SYNJ1's 5-phosphatase domain or knock-down of the kinase PIP5Ks in COS-7 cells leads to severe defects in the internalization and recycling of the transferrin receptors (38). PI(4,5)P<sub>2</sub> metabolism in the adult brain is largely controlled by the 145 kDa isoform of SYNJ1 (26,31) and PIPK1 $\gamma$  (PIP kinase type 1 $\gamma$ ) (39). Transgenic mice overexpressing SYNJ1, and PIPK1 $\gamma$  knock-out mice (PIPK1 $\gamma$ <sup>-/-</sup>) have lower PI(4,5)P<sub>2</sub> levels (21,39). Interestingly, stimulation with high K<sup>+</sup> induces a larger increase in horseradish peroxidase (HRP)-labelled endosome-like endocytic intermediates in PIPK1 $\gamma$ <sup>-/-</sup> neurons when compared with control neurons (39). Interactions with the SH3 domain proteins are regulated by the level of phosphorylation of SYNJ1's proline-rich COOH-terminal tail by Cdk5 and Calcineurin (40,41).

Interestingly, MNB/DYRK1A, a serine-threonine kinase mapping to Hsa21 involved in DS phenotypes, also

phosphorylates SYNJ1 and can regulate its interactions with amphiphysin and intersectin, at least *in vitro* (42). In addition, EphB2 that phosphorylates tyrosines in the proline-rich domain of SYNJ1 inhibits the interaction with endophilin and the 5'-phosphatase activity, leading to increased clathrin-dependant endocytosis (43).

Altogether, these observations suggest that overexpression of SYNJ1 leads to endosomal abnormalities by lowering PI(4,5)P<sub>2</sub> levels. Consistent with this, increase in plasma membrane cholesterol in HEK293 cells was shown to induce a depletion of [PI(4,5)P<sub>2</sub>] and to lead to the formation of enlarged endosomes (44,45). However, a contribution of SYNJ1's NH<sub>2</sub>-terminal SacI region cannot be ruled out, as this catalytic domain can also dephosphorylate PI3P, a lipid that plays a key role in the physiology of endosomes (34).

We confirmed the presence of enlarged endosomes in the cortex of transgenic mice overexpressing Synj1, generated using a bacterial artificial chromosome spanning the region containing the mouse Synj1 gene with two additional unrelated and not well-characterized gene predictions *C21orf59* and *C21orf66*. *C21orf59* does not appear to be expressed in LCLs and is thus unlikely to contribute to the endosomal




**Figure 5.** Transgenic mice overexpressing Synj1 show endosomal abnormalities in prefrontal cortex neurons. **(A)** Western blot analysis of brain extracts from Tg(SYNJ1) ( $n = 4$ ) and WT ( $n = 4$ ) mice probed by anti-SYNJ1 and anti- $\beta$ -actin antibodies. **(B)** Representative confocal images of EEA1-positive early endosomes in neurons of the prefrontal cortex from WT and Tg(SYNJ1) mice. Morphometric analysis of EEA1-positive endosomes were performed in neurons of three WT mice and four Tg(SYNJ1) mice. **(C)** Mean number of EEA1-positive early endosomes in neurons from Tg(SYNJ1) when compared with WT mice. **(D)** Mean endosome size in neurons from Tg(SYNJ1) when compared with WT mice. **(E)** Endosome size distribution of small-, medium- and large-sized endosomes, based on K-means clustering. **(F)** Representation of the WT (green) and Tg(SYNJ1) mice (red) in the plane defined by the percentage of large and small endosomes in their neurons. \*\*\* $P < 0.0001$ , \* $P < 0.05$ .

anomalies in this cell type (23). However, we cannot rule out a putative role of *C21orf66* on the observed phenotype in LCLs.

While we show here a direct functional link between SYNJ1 overexpression and the presence of enlarged endosomes, other genes mapping to Hsa21 have been reported to produce endosomal abnormalities as well. Knock-out mice for Intersectin (*Its1n1*) display abnormally enlarged

endosomes (46). Overexpression of Dyrk1A causes defects in clathrin-mediated endocytosis in fibroblasts (47). In addition, Jiang *et al.* (9) showed that overexpression of APP in fibroblasts from individuals with DS leads to the formation of enlarged endosomes. This result is not in accordance with the finding that APP transgenic mice have apparently normal early endosome morphology in neurons (8). Our



**Figure 6.** Downregulation of SYNJ1 expression in DS fibroblasts by shRNA partially rescues enlarged endosome phenotype. (A) Representative confocal images of EEA1-positive early endosomes (red) from euploid and DS fibroblasts transfected with random-shRNA (green) or *SYNJ1*-shRNA plasmid (green). (B) Mean number of EEA1-positive early endosomes from euploid and DS fibroblasts transfected with random-shRNA or *SYNJ1*-shRNA. (C) Mean endosome size from euploid and DS fibroblasts transfected with random-shRNA or *SYNJ1*-shRNA. (D) Endosome size distribution into small-, medium- and large-sized endosomes, based on K-means clustering. \*\*\* $P < 0.0001$ .

study showed that enlarged endosomes were absent in LCLs carrying APP microduplications, while enlarged endosomes were detected in neurons derived from induced pluripotent stem cells (iPSCs) generated from fibroblasts of two individuals carrying APP microduplications (48). Post-mortem studies in brain sections from patients carrying APP microduplications will be important to clarify the role of APP overexpression on endosomal abnormalities.

Amyloid  $\beta$  ( $A\beta$ ) is produced by enzymatic processing of APP within the endosomal compartment, and intracellular

$A\beta$  was localized principally in enlarged Rab5-positive endosomes in neurons from AD and DS brains (10). Studies reported a link between SYNJ1 and  $A\beta$ . Indeed,  $A\beta_{42}$  oligomers were shown to decrease PI(4,5)P<sub>2</sub> levels and that this decrease was necessary to cause an LTP impairment in hippocampal slices, based on experiments conducted in haploinsufficient *SYNJ1* mice (49). In addition, overexpression of SYNJ1 5'phosphatase domain increased  $A\beta_{42}$  secretion and lowered PI(4,5)P<sub>2</sub> levels (50). Learning deficits in transgenic mice overexpressing SYNJ1 is associated with lower PI(4,5)P<sub>2</sub>

levels, suggesting that treatments using inhibitors of SYNJ1 should restore PI(4,5)P<sub>2</sub> levels and improve synaptic functions in individuals with DS (21,51). Interestingly, an elderly DS patient carrying a partial trisomy with no sign of AD pathology had only two genomic copies of both APP and of SYNJ1 (52).

SYNJ1 is related to two newly identified AD risk factors: PICALM (phosphatidylinositol-binding clathrin assembly protein) involved in clathrin-mediated endocytosis and BIN1 (bridging integrator 1), a brain-specific SH3 domain-containing protein amphiphysin homologue highly enriched in nerve terminals which bind to SYNJ1, dynamin and clathrin (53–57).

Finally, a recent genome-wide screen in yeast for A $\beta$  toxicity identified the orthologue of SYNJ1 as a suppressor, further highlighting the importance of the endocytic machinery in AD (58). Because of its roles in endocytosis and in the regulation of PI(4,5)P<sub>2</sub> levels, SYNJ1 could become an attractive two-faced new AD-DS target for rescuing endocytic dysfunction in DS as shown here and likely in AD, and to modulate A $\beta$  toxicity as demonstrated earlier (49,58).

## MATERIALS AND METHODS

### Cell cultures

#### *Mononuclear blood cells*

Heparinized blood samples were obtained from eight healthy volunteers and eight individuals with DS. All blood donors gave their informed consent to the participation in this study. The mononuclear cell fraction (MNCf) was isolated by carefully loading 4 ml of blood diluted in 8 ml of phosphate buffer saline (PBS) onto 3 ml of Pancoll Separating Solution (PANTMBIOTECH GmbH) at room temperature. After centrifugation 10 min at room temperature at 1000g, the MNCf was collected with a pipette (a membrane prevented contamination with the granulocytes/erythrocytes). The MNCf was washed twice with PBS by centrifugation at 250g for 10 min. Three millions cells per blood sample were re-suspended in RPMI 1640-GlutaMAXTM (Invitrogen) supplemented with 10% FBS (Invitrogen) and transferred to culture dishes for 2 h.

#### *Lymphoblastoid cells lines (LCLs)*

LCLs were derived from B lymphocytes of individuals with DS collected from the cytogenetic service of the hospital Necker Enfants Malades and the Institut Jérôme Lejeune. Parents of patients from the Institut Jérôme Lejeune gave their informed consent, and the French biomedical ethics committee gave its approval for this study (Comité de Protection des Personnes dans la Recherche Biomédicale number 03025). Written informed consent was obtained from the participants or from their families by the cytogenetic service of Hôpital Necker Enfants Malades. Cell lines from control individuals were also obtained with their written informed consent. All cell lines were karyotyped, to confirm their trisomic or euploid status and also to verify that immortalization by the Epstein–Barr virus did not produce any visible chromosomal rearrangement other than trisomy 21. Cells were harvested by centrifugation, washed in 5 ml PBS and stored at

–80°C. Lymphoblastoid cells were grown in Opti-MEM supplemented with 10% fetal bovine serum.

#### *Neuroblastoma cells SH-SY5Y*

SH-SY5Y cells grown in Dubelcco's modified Eagle medium (DMEM) medium F12 supplemented with 10% fetal bovine serum were transfected with the Flag-SYNJ1 long isoform (170 kDa) plasmid (gift from Dr DeCamilli, Yale University School of Medicine, New Haven, CT, USA) using lipofectamin LTX and Plus reagent (Invitrogen) and maintained in culture for 48 h.

#### *Primary fibroblast cultures*

Human forearm skin fibroblasts from individuals with DS and euploid age-matched controls were purchased from Coriell Cell Repositories. Cells were maintained at 37°C and 5% CO<sub>2</sub> and cultured according to the Coriell Cell Repositories's protocol. Cell passage numbers ranged from p7 to p13 and cell confluency was 90%. Nucleofector solution (Amaxa) was used for transfecting SYNJ1-shRNA (purchased from Santa Cruz) and random-shRNA plasmid constructs (pTrip H1 random CMV GFP DeltaU3 Sequence; ccctcgtcatagcgtgcataggtcaggagacctatgcacgctatgacgatttttgaaa) kindly provided by Dr Philippe Ravassard and validated previously (59). Fibroblasts were fixed for EEA1 immunolabelling 72 h after transfection.

#### *HEK293 cells*

HEK293 cells grown in DMEM medium F12 supplemented with 10% fetal bovine serum were transfected with either Flag-SYNJ1-170 human ubiquitous isoform (170 kDa) plasmid or with Flag-SYNJ1-145 human neuronal isoform (145 kDa) DNA plasmids and with random-shRNA, kindly provided by Dr Philippe Ravassard and previously validated (59), or with SYNJ1-shRNA (purchased at Santa Cruz). All DNA plasmid constructs (0.5  $\mu$ g) were transfected using lipofectamin (Invitrogen) and maintained in culture for 72 h.

### Immunofluorescence

After fixation (paraformaldehyde 4%), cells were washed with PBS, permeabilized using triton (0.1%) and incubated 1 h with either the rabbit polyclonal anti-EEA1 antibody (1/200, Cell Signaling) or the sheep polyclonal anti-SOD1 antibody or the mouse monoclonal Flag M2 antibody (Sigma). Alexa-568- or Alexa-488-labelled secondary antibodies (Molecular Probes, 1/400) were used to reveal the primary antibody and incubated for 30 min. Images (1024  $\times$  1024 pixels) of individual cells were obtained on a Leica TCS NT confocal microscope using a  $\times$ 63, numerical aperture 1.4 oil immersion objective and  $\times$ 6 zoom. Each picture was obtained from the equatorial cross-section through the cell that maximized nuclear diameter, under signal saturation. Co-detection of Alexa-488 and Alexa-568 fluorescence was done by excitation at 488 and 568 nm, using sequential detection. The zoom was set up to achieve a final pixel resolution of 80  $\mu$ m.

### Protein extraction and immunoblots

Cells were washed twice and proteins were extracted for 2 h in a Tris buffer 0.05 M containing 0.1 M NaCl, 5 mM ethylenediaminetetraacetic acid, 1% Nonidet P-40 and a protease inhibitor cocktail (Roche). Cell debris were removed by centrifugation at 13000g. Protein concentration was determined using the Dc protein assay kit (BIO-RAD). Frozen brains were homogenized for western blot analysis, and 50 µg of total protein per lane were loaded on a 4–12% gradient Bis–Tris gels under reducing conditions. Proteins were transferred on nitrocellulose membranes (Whatman) that were hybridized with Rab5a (Santa Cruz), rabbit polyclonal antibody to the C-terminus of SYNJ1 (gift from Dr DeCamilli) or Actin (Abcam) antibodies. After incubation with horseradish peroxidase-conjugated secondary antibodies (Molecular Probes), signal was revealed using Immobilon western chemoluminescent HRP substrate (Millipore).

### RNA extraction and real-time quantitative PCR

One microgram of each RNA was individually reverse-transcribed into cDNAs overnight at 37°C using the Verso cDNA kit (ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. qPCR assays were performed in a Lightcycler® 480 System (Roche), in the presence of 200 nM of each primer, 100 nM of specific hydrolysis probe (designed with Universal Probe Library, Roche Applied Science) and 1 × Lightcycler® 480 Probes Master mix (Roche, France) and normalized using the Lightcycler® 480 SW 1.5 software and two normalization genes: PolR2A and RNF4. Primers were GATGGTCAAGGTCGCAAG-forward, GAATTTCAAATCCAACAAAGTCTG-reverse and ATCTGGTCCTAGTCACTGG-probe for SYNJ1; CCAAT TTCATGAATTTCAAGAGAG-forward, TCAAACCTTACT GTAGTGCATC-reverse and AGAAAAGCAGCCCCAA TG-probe for RAB5; TGGACAGGCAAGCAAATC-forward, CAGAGACTTCTTACACAGGATG-reverse and TCTCCAC CACCACCTTG-probe for PolR2A; CTCAGGTACTGTCA GTTGTC-forward, CGATGAGACGTCCATTCTG-reverse and TCTGAGTATCCGTCCATGC-probe for RNF4.

### Mapping of partial trisomies 21 using ultra-high resolution CGH

For detailed structural Hsa21 aberration detection, high-resolution array-CGH with NimbleGen HG18 chromosome 21-specific 385K arrays was used (B3752001-00-01; Roche NimbleGen Systems, Madison, WI, USA). The 385K average probe distance was 70 bp. DNA labelling, array hybridization, post-hybridization washes and scanning were essentially performed according to the manufacturer's instructions (Roche NimbleGen). The acquired images were analysed using NimbleScan V2.4 extraction software (Roche NimbleGen). For each probe on the array, the log<sub>2</sub> Cy3/Cy5 ratio (relative intensity of the Cy3 labelled patient DNA versus the Cy5-labelled male DNA reference pool of five healthy male individuals) was calculated using the segMNT algorithm, which also applied an automatic segment detection. A 50 × averaging window was generated, resulting in 3500 bp segments for this

array. Previously determined breakpoints (e.g. by cytogenetic or other array-CGH means) were re-analysed and fine-mapped using the 3.5 kb averaging window accuracy. Data were visualized in SignalMap V1.9 software (Roche NimbleGen).

### Immunohistochemistry on brain slices from Tg(SYNJ1) and wild-type mice

Mice were anaesthetized. Two groups of mice were used in this experiment. In the first group, mice [three WT and four Tg(SYNJ1)] were perfused transcardially with 4% paraformaldehyde in 0.1 M Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> buffer (pH 7.5). Brains were extracted, post-fixed overnight in the fixative solution used for perfusion and stored at 4°C. In the second group (four WT and four Tg(SYNJ1)), brains were extracted and split up into two parts. Half of the brains were incubated in formol, and the other halves were used for biochemical studies. Sections (30 µm thick) were cut with a Vibratome (Leica) and kept at –20°C until use in a solution containing 30% (vol/vol) ethylene glycol, 30% (vol/vol) glycerol and 0.1 M phosphate buffer. Floating sections were saturated for 1 h with 10% normal goat serum in Tris–buffered saline (TBS: 25 mM Tris-Cl, 150 mM NaCl, pH 7.4). Sections were then rinsed three times in TBS and incubated with a rabbit anti-EEA1 antibody (1/200, Cell Signalling) and a MAP2 mouse antibody specific of neuronal cells (60) (1/200, Chemicon) followed by anti-rabbit-Alexa-488 and anti-mouse-Alexa-568 (Invitrogen) (1/500). Sections were mounted in Vectashield with 4',6-diamidino-2-phenylindole counterstain (Vector Laboratories). Images (1024 × 1024 pixels) of individual cells were obtained on a Leica TCS NT confocal microscope using a ×63, numerical aperture 1.4 oil immersion objective and ×6 zoom. The zoom was set up to achieve a final pixel resolution of 80 µm.

### Morphometric analysis of endosomes

Images of individual cells were analysed using the spot detector plugin (id ICY-R3M2Y2) of ICY (<http://icy.bioimageanalysis.org>). The spot detector extracts spots in images using an undecimated wavelet transform (61,62). The number and size of endosomes were measured in 12–22 individual cells from mononuclear blood cells of 8 controls and 8 individuals with DS and LCLs of 9 controls and 12 individuals with DS. For SH-SY5Y neuroblastoma cells, analyses were performed on 31 non-transfected cells, 32 cells transfected with the GFP plasmid and 34 cells transfected with the SYNJ1 plasmid. For the analysis of mouse brains, the number and size of endosomes was measured in 9–15 individual neurons in the prefrontal cortex from WT and Tg(SYNJ1) mice. Finally, for fibroblast cells, analysis was performed on 20 non-transfected cells, and 45 cells transfected with either SYNJ1-shRNA or random-shRNA constructs.

### Statistical analysis

For the morphometric analysis of the endosomes, three parameters were taken into consideration: the mean number of endosomes per cell, the mean endosome size and the endosome size distribution. Table 1 summarizes,

for each experiment, the conditions that were to be compared, and the number of samples analysed (individuals, cells or mice).

#### *Comparison of the mean numbers of endosomes per cell*

For the mononuclear blood cells, the prefrontal cortical neurons and the LCL experiments, the comparison of the mean numbers of endosomes per cell was performed between two conditions, with a varying number of cells per individual. Assuming constant variance of the endosome number across individuals or mice, the variance of the mean endosome number for each condition is hence inversely proportional to the number of cells from which it is estimated. Thus, the estimation of the effects (means) and of the significance of their difference was performed using weighted least squares (WLS), each squared error being weighted by the inverse of the number of cells.

The analysis of the SH SY5Y experiment involved three conditions: non-transfected, GFP transfected and SYNJ1 transfected. Thus, a one-way analysis of variance was performed. The latter showing a difference in means, it was followed by pairwise comparisons (*t*-tests without corrections for multiple testing).

The primary fibroblast experiments were performed from one individual with DS, and one age-matched euploid (21 years old), with 20 cells for each. Thus, a standard *t*-test was used to establish the non-significance of the mean endosome size difference between the two genotypes.

Finally, the fibroblast experiment involving an euploid control and a DS patient, 45 cells of each being transfected with random shRNA, and 45 other cells with SYNJ1-shRNA, a two-way ANOVA was used to establish that the effects of both genotype and treatment were not significant.

#### *Comparison of the mean endosome sizes*

For the mononuclear blood cells, the prefrontal cortical neurons and the LCLs experiments, the comparison of the mean endosome size was performed between two conditions, with a varying number of endosomes per cell. Since the mean endosome size sometimes clearly varied from one sample to the other (individual or mouse), we thus systematically added an individual factor (fixed) to the genotype factor, and tested its significance as well. Since the factors are nested, there was no interaction. As before, we used WLS for the analysis but this time, the weighting was performed according to the number of endosomes for each cell. The primary fibroblast experiment involved the same test, except that no individual effect had to be tested.

The analysis of the SH-SY5Y again involved three conditions. There was no individual effect to add, but since the comparison of three means had to take into account the varying number of endosomes per cell, we also used WLS.

Finally, the fibroblast experiments involved four conditions, depending on genotype (euploid or DS) and treatment (random shRNA or SYNJ1-shRNA), without individual effect. We performed the test of genotype, condition and interaction, taking the varying number of endosomes per cell into account.

#### *Comparison of the endosome size distributions*

Although the effect of the individual sometimes proved significant, we considered the overall distribution of the endosome size. For each experiment, endosomes were classified into three groups (small, medium and large size) using K-means clustering. The homogeneity of the distributions across conditions was then tested with a  $\chi^2$ -test. For some of the experiments, in order to account for the possible individual effect that is neglected when pooling the endosome of all individuals, we also plotted the individual in the plane defined by their (individual) percentages of small (on the *x*-axis) and large (on the *y*-axis) endosomes.

#### *Classification of the partial trisomies for the genotype–phenotype correlation*

In order to analyse the LCLs from partial trisomies and to classify them as euploids (no endosomal abnormalities) or DS (presence of enlarged endosomes), for each of them we tested the homogeneity of the distribution of their endosome size with that of the euploid and DS LCLs, the criterion for classification into small, medium and large endosomes being the one obtained previously with the K-means on the euploid and DS LCLs. For the majority of the LCLs from partial trisomies, the two  $\chi^2$  tests led to opposite decisions with a type I error risk of 5% (the partial trisomy was homogeneous with one phenotype and not with the other), thus allowing univocal classification. For some LCLs, the tests failed to reject one of the phenotypes: LCLs with  $P_{DS} > P_{euploid} > 5\%$  were considered to have the enlarged endosome phenotype, LCLs with  $P_{euploid} > P_{DS} > 5\%$  were not.

Correlations of endosomal abnormalities in LCLs from individual with partial T21 with gene expression levels were evaluated using Pearson's correlation coefficient. Because of the small sample size ( $n = 8$ ), we avoided the use of non-parametric correlation measures such as Spearman's or Kendall's coefficients.

## SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

## ACKNOWLEDGEMENTS

The authors wish to thank Drs DeCamilli and Ravassard for their gift of plasmids, and Dr Menten from the Department of Pediatrics and Medical Genetics, Gent University, Belgium for providing material of case 5.

*Conflict of Interest statement.* None declared.

## FUNDING

This work was supported by the Agence Nationale de la Recherche (ChoAD to M.-C.P. and C.D.); the European Communities (AnEUploidy to M.-C.P., A.H., Y.G., S.E.A., J.A.V. and J.M.D.); the Fondation ICM and the Fondation Thierry et Annick Desmaret-Institut de France to M.C.P. and C.D.; the National Institutes of Health (R01 HD055457 to G.D.P.); and the Foundation Jerome Lejeune to G.D.P.

## REFERENCES

- Cataldo, A.M., Barnett, J.L., Pieroni, C. and Nixon, R.A. (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. *J. Neurosci.*, **17**, 6142–6151.
- Cataldo, A.M., Peterhoff, C.M., Troncoso, J.C., Gomez-Isla, T., Hyman, B.T. and Nixon, R.A. (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. *Am. J. Pathol.*, **157**, 277–286.
- Thinakaran, G. and Koo, E.H. (2008) Amyloid precursor protein trafficking, processing, and function. *J. Biol. Chem.*, **283**, 29615–29619.
- Delabar, J.M., Goldgaber, D., Lamour, Y., Nicole, A., Huret, J.L., de Grouchy, J., Brown, P., Gajdusek, D.C. and Sinet, P.M. (1987) Beta amyloid gene duplication in Alzheimer's disease and karyotypically normal Down syndrome. *Science*, **235**, 1390–1392.
- Goldgaber, D., Lerman, M.I., McBride, O.W., Saffiotti, U. and Gajdusek, D.C. (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. *Science*, **235**, 877–880.
- Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K. and Muller-Hill, B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature*, **325**, 733–736.
- Tanzi, R.E., Gusella, J.F., Watkins, P.C., Bruns, G.A., St George-Hyslop, P., Van Keuren, M.L., Patterson, D., Pagan, S., Kurnit, D.M. and Neve, R.L. (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science*, **235**, 880–884.
- Cataldo, A.M., Petanceska, S., Peterhoff, C.M., Terio, N.B., Epstein, C.J., Villar, A., Carlson, E.J., Staufenbiel, M. and Nixon, R.A. (2003) App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. *J. Neurosci.*, **23**, 6788–6792.
- Jiang, Y., Mullaney, K.A., Peterhoff, C.M., Che, S., Schmidt, S.D., Boyer-Boiteau, A., Ginsberg, S.D., Cataldo, A.M., Mathews, P.M. and Nixon, R.A. (2009) Alzheimer's-related endosome dysfunction in Down syndrome is A $\beta$ -independent but requires APP and is reversed by BACE-1 inhibition. *Proc. Natl Acad. Sci. USA*, **107**, 1630–1635.
- Cataldo, A.M., Petanceska, S., Terio, N.B., Peterhoff, C.M., Durham, R., Mercken, M., Mehta, P.D., Buxbaum, J., Haroutunian, V. and Nixon, R.A. (2004) Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. *Neurobiol. Aging*, **25**, 1263–1272.
- Cataldo, A.M., Mathews, P.M., Boiteau, A.B., Hassinger, L.C., Peterhoff, C.M., Jiang, Y., Mullaney, K., Neve, R.L., Gruenberg, J. and Nixon, R.A. (2008) Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. *Am. J. Pathol.*, **173**, 370–384.
- Ginsberg, S.D., Alldred, M.J., Counts, S.E., Cataldo, A.M., Neve, R.L., Jiang, Y., Wu, J., Chao, M.V., Mufson, E.J., Nixon, R.A. *et al.* (2010) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. *Biol. Psychiatry*, **68**, 885–893.
- Roberts, R.L., Barbieri, M.A., Pryse, K.M., Chua, M., Morisaki, J.H. and Stahl, P.D. (1999) Endosome fusion in living cells overexpressing GFP-rab5. *J. Cell Sci.*, **112**, 3667–3675.
- Nixon, R.A. (2005) Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. *Neurobiol. Aging*, **26**, 373–382.
- Cataldo, A., Rebeck, G.W., Ghetti, B., Hulette, C., Lippa, C., Van Broeckhoven, C., van Duijn, C., Cras, P., Bogdanovic, N., Bird, T. *et al.* (2001) Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. *Ann. Neurol.*, **50**, 661–665.
- Lyle, R., Bena, F., Gagos, S., Gehrig, C., Lopez, G., Schinzel, A., Lespinasse, J., Bottani, A., Dahoun, S., Taine, L. *et al.* (2009) Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. *Eur. J. Hum. Genet.*, **17**, 454–466.
- Korbel, J.O., Tirosh-Wagner, T., Urban, A.E., Chen, X.N., Kasowski, M., Dai, L., Grubert, F., Erdman, C., Gao, M.C., Lange, K. *et al.* (2009) The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. *Proc. Natl Acad. Sci. USA*, **106**, 12031–12036.
- Mani, M., Lee, S.Y., Lucast, L., Cremona, O., Di Paolo, G., De Camilli, P. and Ryan, T.A. (2007) The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. *Neuron*, **56**, 1004–1018.
- Chang-Ileto, B., Frere, S.G., Chan, R.B., Voronov, S.V., Roux, A. and Di Paolo, G. (2011) Synaptojanin 1-mediated PI(4,5)P2 hydrolysis is modulated by membrane curvature and facilitates membrane fission. *Dev. Cell*, **20**, 206–218.
- Arai, Y., Ijuin, T., Takenawa, T., Becker, L.E. and Takashima, S. (2002) Excessive expression of synaptojanin in brains with Down syndrome. *Brain Dev.*, **24**, 67–72.
- Voronov, S.V., Frere, S.G., Giovedi, S., Pollina, E.A., Borel, C., Zhang, H., Schmidt, C., Akeson, E.C., Wenk, M.R., Cimasoni, L. *et al.* (2008) Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. *Proc. Natl Acad. Sci. USA*, **105**, 9415–9420.
- Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M. *et al.* (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat. Genet.*, **38**, 24–26.
- Ait Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., Golfier, G., Rossier, J., Personnaz, L., Creau, N., Blehaut, H. *et al.* (2007) Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. *Am. J. Hum. Genet.*, **81**, 475–491.
- Prandini, P., Deutsch, S., Lyle, R., Gagnebin, M., Delucinge Vivier, C., Delorenzi, M., Gehrig, C., Descombes, P., Sherman, S., Dagna Bricarelli, F. *et al.* (2007) Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. *Am. J. Hum. Genet.*, **81**, 252–263.
- Cremona, O., Nimmakayalu, M., Haffner, C., Bray-Ward, P., Ward, D.C. and De Camilli, P. (2000) Assignment of SYNJ1 to human chromosome 21q22.2 and Synj12 to the murine homologous region on chromosome 16C3–4 by in situ hybridization. *Cytogenet. Cell Genet.*, **88**, 89–90.
- Kim, W.T., Chang, S., Daniell, L., Cremona, O., Di Paolo, G. and De Camilli, P. (2002) Delayed reentry of recycling vesicles into the fusion-competent synaptic vesicle pool in synaptojanin 1 knockout mice. *Proc. Natl Acad. Sci. USA*, **99**, 17143–17148.
- Cheon, M.S., Kim, S.H., Ovod, V., Kopitar Jerala, N., Morgan, J.I., Hatefi, Y., Ijuin, T., Takenawa, T. and Lubec, G. (2003) Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part III). *Amino Acids*, **24**, 127–134.
- Moldrich, R.X., Laine, J., Visel, A., Beart, P.M., Laffaire, J., Rossier, J. and Potier, M.C. (2008) Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neurophenotypes, encodes an intracellular membrane protein expressed in the rodent brain. *Neuroscience*, **154**, 1255–1266.
- Wynn, S.L., Fisher, R.A., Pagel, C., Price, M., Liu, Q.Y., Khan, I.M., Zammit, P., Dadrah, K., Mazrani, W., Kessler, A. *et al.* (2000) Organization and conservation of the GART/SON/DONSON locus in mouse and human genomes. *Genomics*, **68**, 57–62.
- Epstein, C.J. (1997) 1996 ASHG Presidential Address. Toward the 21st century. *Am. J. Hum. Genet.*, **60**, 1–9.
- Cremona, O., Di Paolo, G., Wenk, M.R., Luthi, A., Kim, W.T., Takei, K., Daniell, L., Nemoto, Y., Shears, S.B., Flavell, R.A. *et al.* (1999) Essential role of phosphoinositide metabolism in synaptic vesicle recycling. *Cell*, **99**, 179–188.
- Di Paolo, G. and De Camilli, P. (2006) Phosphoinositides in cell regulation and membrane dynamics. *Nature*, **443**, 651–657.
- Haffner, C., Di Paolo, G., Rosenthal, J.A. and de Camilli, P. (2000) Direct interaction of the 170 kDa isoform of synaptojanin 1 with clathrin and with the clathrin adaptor AP-2. *Curr. Biol.*, **10**, 471–474.
- Chang, K.T. and Min, K.T. (2009) Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: implications for Down syndrome. *Proc. Natl Acad. Sci. USA*, **106**, 17117–17122.
- Mishra, S.K., Hawryluk, M.J., Brett, T.J., Keyel, P.A., Dupin, A.L., Jha, A., Heuser, J.E., Fremont, D.H. and Traub, L.M. (2004) Dual engagement regulation of protein interactions with the AP-2 adaptor alpha appendage. *J. Biol. Chem.*, **279**, 46191–46203.



36. Perera, R.M., Zoncu, R., Lucast, L., De Camilli, P. and Toomre, D. (2006) Two synaptojanin 1 isoforms are recruited to clathrin-coated pits at different stages. *Proc. Natl Acad. Sci. USA*, **103**, 19332–19337.
37. Micheva, K.D., Kay, B.K. and McPherson, P.S. (1997) Synaptojanin forms two separate complexes in the nerve terminal. Interactions with endophilin and amphiphysin. *J. Biol. Chem.*, **272**, 27239–27245.
38. Kim, S., Kim, H., Chang, B., Ahn, N., Hwang, S., Di Paolo, G. and Chang, S. (2006) Regulation of transferrin recycling kinetics by PtdIns[4,5]P<sub>2</sub> availability. *FASEB J.*, **20**, 2399–2401.
39. Di Paolo, G., Moskowitz, H.S., Gipson, K., Wenk, M.R., Voronov, S., Obayashi, M., Flavell, R., Fitzsimonds, R.M., Ryan, T.A. and De Camilli, P. (2004) Impaired PtdIns(4,5)P<sub>2</sub> synthesis in nerve terminals produces defects in synaptic vesicle trafficking. *Nature*, **431**, 415–422.
40. Slepnev, V.I., Ochoa, G.C., Butler, M.H., Grabs, D. and De Camilli, P. (1998) Role of phosphorylation in regulation of the assembly of endocytic coat complexes. *Science*, **281**, 821–824.
41. Lee, S.Y., Wenk, M.R., Kim, Y., Nairn, A.C. and De Camilli, P. (2004) Regulation of synaptojanin 1 by cyclin-dependent kinase 5 at synapses. *Proc. Natl Acad. Sci. USA*, **101**, 546–551.
42. Adayev, T., Chen-Hwang, M.C., Murakami, N., Wang, R. and Hwang, Y.W. (2006) MNB/DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins. *Biochem. Biophys. Res. Commun.*, **351**, 1060–1065.
43. Irie, F., Okuno, M., Pasquale, E.B. and Yamaguchi, Y. (2005) EphrinB-EphB signalling regulates clathrin-mediated endocytosis through tyrosine phosphorylation of synaptojanin 1. *Nat. Cell Biol.*, **7**, 501–509.
44. Chun, Y.S., Shin, S., Kim, Y., Cho, H., Park, M.K., Kim, T.W., Voronov, S.V., Di Paolo, G., Suh, B.C. and Chung, S. (2010) Cholesterol modulates ion channels via down-regulation of phosphatidylinositol 4,5-bisphosphate. *J. Neurochem.*, **112**, 1286–1294.
45. Cossec, J.C., Marquer, C., Panchal, M., Lazar, A.N., Duyckaerts, C. and Potier, M.C. (2010) Cholesterol changes in Alzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes. *Biochim. Biophys. Acta*, **1801**, 839–845.
46. Yu, Y., Chu, P.Y., Bowser, D.N., Keating, D.J., Dubach, D., Harper, I., Tkalcevic, J., Finkelstein, D.I. and Pritchard, M.A. (2008) Mice deficient for the chromosome 21 ortholog Itsn1 exhibit vesicle-trafficking abnormalities. *Hum. Mol. Genet.*, **17**, 3281–3290.
47. Kim, Y., Park, J., Song, W.J. and Chang, S. (2010) Overexpression of Dyrk1A causes the defects in synaptic vesicle endocytosis. *Neurosignals*, **18**, 164–172.
48. Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S. *et al.* (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature*, **482**, 216–220.
49. Berman, D.E., Dall'Armi, C., Voronov, S.V., McIntire, L.B., Zhang, H., Moore, A.Z., Staniszewski, A., Arancio, O., Kim, T.W. and Di Paolo, G. (2008) Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. *Nat. Neurosci.*, **11**, 547–554.
50. Landman, N., Jeong, S.Y., Shin, S.Y., Voronov, S.V., Serban, G., Kang, M.S., Park, M.K., Di Paolo, G., Chung, S. and Kim, T.W. (2006) Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. *Proc. Natl Acad. Sci. USA*, **103**, 19524–19529.
51. Di Paolo, G. and Kim, T.W. (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. *Nat. Rev. Neurosci.*, **12**, 284–296.
52. Prasher, V.P., Farrer, M.J., Kessling, A.M., Fisher, E.M., West, R.J., Barber, P.C. and Butler, A.C. (1998) Molecular mapping of Alzheimer-type dementia in Down's syndrome. *Ann. Neurol.*, **43**, 380–383.
53. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Pahwa, J.S., Moskvin, V., Dowzell, K., Williams, A. *et al.* (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat. Genet.*, **41**, 1088–1093.
54. Miller, J.A., Horvath, S. and Geschwind, D.H. (2010) Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. *Proc. Natl Acad. Sci. USA*, **107**, 12698–12703.
55. Baig, S., Joseph, S.A., Tayler, H., Abraham, R., Owen, M.J., Williams, J., Kehoe, P.G. and Love, S. (2010) Distribution and expression of picalm in Alzheimer disease. *J. Neuropathol. Exp. Neurol.*, **69**, 1071–1077.
56. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., Hamshere, M.L., Pahwa, J.S., Moskvin, V. *et al.* (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat. Genet.*, **43**, 429–435.
57. Ramjaun, A.R., Micheva, K.D., Bouchelet, I. and McPherson, P.S. (1997) Identification and characterization of a nerve terminal-enriched amphiphysin isoform. *J. Biol. Chem.*, **272**, 16700–16706.
58. Treusch, S., Hamamichi, S., Goodman, J.L., Matlack, K.E., Chung, C.Y., Baru, V., Shulman, J.M., Parrado, A., Bevis, B.J., Valastyan, J.S. *et al.* (2011) Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. *Science*, **334**, 1241–1245.
59. Collombat, P., Xu, X., Ravassard, P., Sosa-Pineda, B., Dussaud, S., Billestrup, N., Madsen, O.D., Serup, P., Heimberg, H. and Mansouri, A. (2009) The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. *Cell*, **138**, 449–462.
60. Salthun-Lassalle, B., Hirsch, E.C., Wolfart, J., Ruberg, M. and Michel, P.P. (2004) Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. *J. Neurosci.*, **24**, 5922–5930.
61. Olivo-Marin, J.C. (2002) Extraction of spots in biological images using multiscale products. *Pattern Recognition*, **35**, 1989–1996.
62. Avale, M.E., Chabout, J., Pons, S., Serreau, P., De Chaumont, F., Olivo-Marin, J.C., Bourgeois, J.P., Maskos, U., Changeux, J.P. and Granon, S. (2011) Prefrontal nicotinic receptors control novel social interaction between mice. *FASEB J.*, **25**, 2145–2155.